Branch A D, Klotman P E
Division of Liver Diseases (Department of Medicine), Mount Sinai Medical Center, New York, N.Y. 10029, USA.
Exp Nephrol. 1998 Jan-Feb;6(1):78-83.
Therapeutic ribozymes are created through a multistep process that requires trial and error. There are few established rules governing ribozyme design, but guidelines are emerging. It is not yet known whether hammerheads and hairpins, the two ribozymes most widely studied as potential gene therapy agents, have the inherent capability to ablate single genes. Their capacity for specificity and selectivity remains to be explored through rigorous experimentation. These experiments require a battery of control molecules, the characteristics of which are outlined here. Methods for completing the steps in the ribozyme development process, from the selection of a target gene to the quantitation of RNA levels, are also presented and discussed.
治疗性核酶是通过一个需要反复试验的多步骤过程产生的。目前几乎没有既定的规则来指导核酶设计,但相关指导原则正在不断涌现。作为潜在基因治疗剂被广泛研究的两种核酶——锤头状核酶和发夹状核酶——是否具有敲除单个基因的内在能力,目前尚不清楚。它们的特异性和选择性仍有待通过严格的实验来探索。这些实验需要一系列对照分子,其特性在此进行了概述。本文还介绍并讨论了从靶基因选择到RNA水平定量的核酶开发过程中各个步骤的完成方法。